<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211626</url>
  </required_header>
  <id_info>
    <org_study_id>ANA773-601</org_study_id>
    <nct_id>NCT01211626</nct_id>
  </id_info>
  <brief_title>Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study in Healthy Volunteers and Patients With Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANA773 Tosylate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall study design includes two parts, Part A and Part B.

      Part A evaluated ANA773 following oral administration to healthy volunteers. A total of 40
      evaluable healthy volunteers were enrolled in Part A of the study.

      Part B evaluated ANA773 following oral administration to patients with chronic HCV infection.
      A total of 34 evaluable patients were enrolled in Part B of this study in 2 study centers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      Part A evaluated ANA773 following oral administration to healthy volunteers. A total of 40
      evaluable healthy volunteers were enrolled in Part A of the study.

      Part B evaluated ANA773 following oral administration to patients with chronic HCV infection.
      A total of 34 evaluable patients were enrolled in Part B of this study in 2 study centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Pharmacokinetic Analysis in both Healthy Subjects and Chronic HCV Patients</measure>
    <time_frame>Up to 41 Days</time_frame>
    <description>Evaluate the Safety and Pharmacokinetic Analysis in both Healthy Subjects and Chronic HCV Patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological effects in both Healthy Subjects and Chronic HCV Patients</measure>
    <time_frame>Up to 41 days</time_frame>
    <description>Evaluate the immunological effects and antiviral activity as assessed by changes in HCV RNA levels.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Part A, Group 1 Healthy Volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 2 Healthy Volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 3 Healthy Volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 4 Healthy Volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 5 Healthy Volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 6 HCV Infected Patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 7 HCV Infected Patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 8 HCV Infected Patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 9 HCV Infected Patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANA773</intervention_name>
    <description>ANA773 Tosylate Capsule</description>
    <arm_group_label>Part A, Group 1 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 2 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 3 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 4 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 5 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part B, Group 6 HCV Infected Patient</arm_group_label>
    <arm_group_label>Part B, Group 7 HCV Infected Patient</arm_group_label>
    <arm_group_label>Part B, Group 8 HCV Infected Patient</arm_group_label>
    <arm_group_label>Part B, Group 9 HCV Infected Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo Capsule</description>
    <arm_group_label>Part A, Group 1 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 2 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 3 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 4 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part A, Group 5 Healthy Volunteer</arm_group_label>
    <arm_group_label>Part B, Group 6 HCV Infected Patient</arm_group_label>
    <arm_group_label>Part B, Group 7 HCV Infected Patient</arm_group_label>
    <arm_group_label>Part B, Group 8 HCV Infected Patient</arm_group_label>
    <arm_group_label>Part B, Group 9 HCV Infected Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A Inclusion:

          -  Male or female, ages 18 to 65 years

          -  No clinically significant abnormalities

          -  No serious or severe chronic conditions

          -  Non-smokers

        Part A Exclusion:

          -  Female subjects who are pregnant or breast-feeding

          -  History of significant medical condition that could interfere with study medication or
             associated study assessments

          -  History of or current drug or alcohol abuse

        Part B Inclusion Criteria:

          -  Male or female, ages 18 to 65 years

          -  Diagnosed with chronic liver disease consistent with chronic hepatitis C infection for
             at least 6 months

          -  Screening HCV RNA ≥ 375,000 copies/mL or ≥ 75,000 IU/mL

          -  Naïve to or have relapsed from prior IFN-alpha based therapy

        Part B Exclusion Criteria:

          -  Female subjects who are pregnant or breast-feeding

          -  Received anti-viral therapy or immunomodulatory therapy within 90 days prior to
             administration of the first dose of study medication

          -  Use of an investigational drug or participation in an investigational study with a
             licensed drug within 30 days

          -  History of significant medical condition that could interfere with study medication or
             associated study assessments

          -  History of or current drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Clinical Research Unit</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC (EMC)</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>November 12, 2012</last_update_submitted>
  <last_update_submitted_qc>November 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

